The in vitro antibacterial activities of ceftazidime-avibactam and comparator agents were evaluated using reference broth microdilution methods against 1,743 Pseudomonas aeruginosa isolates collected in 2014 from 69 U.S. medical centers, representing each of the nine census regions. Ceftazidime-avibactam demonstrated potent activity against P. aeruginosa, including many isolates not susceptible to ceftazidime, meropenem, and piperacillin-tazobactam. In each of the nine census regions, ceftazidimeavibactam demonstrated the highest percentage of susceptible isolates.
I
ncreasing occurrence of antimicrobial resistance in Gram-negative bacilli, including Enterobacteriaceae and Pseudomonas aeruginosa, has complicated the treatment of serious nosocomial infections. ␤-Lactam antibacterials, which were once highly effective against these pathogens, have been compromised by isolates that harbor resistance due to the production of extended-spectrum ␤-lactamases (ESBLs) and carbapenemases (1) (2) (3) (4) , along with other resistance mechanisms, including efflux and porin loss (5, 6 ) and the recent emergence of plasmid-mediated resistance to colistin (7) . The spread of ␤-lactamases is particularly problematic due to the potential for additional mutations that can broaden their spectrum of hydrolysis, as well as their ability to disseminate to other pathogens. Ceftazidime-avibactam is the combination of the established third-generation cephalosporin ceftazidime and the novel non-␤-lactam ␤-lactamase inhibitor avibactam. Avibactam inhibits a broad range of serine ␤-lactamases, including Ambler class A (ESBL and Klebsiella pneumoniae carbapenemase), class C (AmpC), and some class D (OXA-48) enzymes. When used in combination with ceftazidime, avibactam restores the activity of ceftazidime against a number of clinically relevant ␤-lactamase-producing Gram-negative pathogens that cause serious infections (8) . We evaluated the in vitro antibacterial activities and susceptibility patterns of ceftazidime-avibactam and comparator compounds against P. aeruginosa surveillance isolates obtained in 2014 from a variety of infection types (skin and soft tissue, urinary tract, intra-abdominal, and others) from each of the nine census regions within the United States.
A total of 1,743 P. aeruginosa isolates collected in 2014 from 69 medical centers within the nine U.S. census regions were included in the International Network for Optimal Resistance Monitoring (INFORM) surveillance program. Broth microdilution susceptibility testing for ceftazidime-avibactam, ceftazidime, cefepime, meropenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, amikacin, gentamicin, and colistin was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines (9) using validated MIC panels produced by Thermo Fisher Scientific (Cleveland, OH). Susceptibility interpretive criteria for comparator compounds included both CLSI (10) and EUCAST (European Committee on Antimicrobial Susceptibility Testing) (11) breakpoint criteria, when available. The recently approved U.S. Food and Drug Administration (FDA) breakpoint interpretative criteria were applied for ceftazidime-avibactam (12) . Qualitycontrol (QC) testing included the following reference bacterial strains: Escherichia coli ATCC 25922, E. coli ATCC 35218, Klebsiella pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853. All QC results for ceftazidime-avibactam and comparator compounds were within published ranges (10) . Ceftazidimenonsusceptible and meropenem-nonsusceptible isolates displayed intermediate or resistant MIC values (Ն16 or Ն4 g/ ml, respectively) according to published breakpoint criteria (10, 11) . Table 1 lists ceftazidime-avibactam and comparator compound susceptibility testing results against 1,743 P. aeruginosa isolates collected in 2014, including the number of isolates tested, the MIC 50 , the MIC 90 , and the percentages of susceptible, intermediate, and resistant isolates by U.S. census region, categorized according to CLSI, EUCAST, and/or FDA breakpoint interpretive criteria. Ceftazidime-avibactam activity (MIC 50/90 , 2/8 g/ml; 96.3% susceptible at Յ8 g/ml) against all 1,743 P. aeruginosa isolates was enhanced over that with ceftazidime when tested alone (MIC 50/90 , 2/32 g/ml; 84.0% susceptible at Յ8 g/ml; Fig.  1 ; Table 1 ) and was more active than the other ␤-lactam comparators, including cefepime, meropenem, and piperacillin-tazobactam (86.5%, 83.0%, and 83.0% susceptible, respectively).
The addition of avibactam to ceftazidime increased the percentages of susceptible P. aeruginosa isolates across each of the census regions from 7.4% (West North Central region) to 16.3% (east South Central region) over those of ceftazidime tested alone ( Table 1 ). The greatest restorations of ceftazidime activity by avibactam against P. aeruginosa were observed in the New England and East South Central regions (16.0% and 16.3%, respec- Susceptibilities were lowest for ceftazidime, cefepime, and piperacillin-tazobactam against P. aeruginosa (79.1%, 81.0%, and 75.2% susceptible, respectively) in the East South Central region (95.4% susceptible to ceftazidime-avibactam) and for meropenem (77.7%) in the Mountain region (97.0% susceptible to ceftazidime-avibactam). Susceptibilities to ceftazidime-avibactam were lowest for P. aeruginosa in the Pacific region (91.5% susceptible); however, ceftazidime-avibactam remained more active than the ceftazidime, cefepime, meropenem, and piperacillintazobactam, fluoroquinolone (ciprofloxacin and levofloxacin), and aminoglycoside (gentamicin) comparators, with the exceptions of amikacin and colistin (93.0% and 100.0% susceptible, respectively; Table 1 ). Susceptibilities of P. aeruginosa to ceftazidime-avibactam were highest in the New England and West North Central regions (100.0% and 99.0% susceptible, respectively). Similarly, susceptibilities to ceftazidime, cefepime, meropenem, and piperacillin-tazobactam were also highest (91.6% to 94.8% susceptible) in the West North Central region.
In vitro ceftazidime-avibactam activities were evaluated against resistant subgroups of P. aeruginosa ( Fig. 2; Table 2 ), including ceftazidime-nonsusceptible (n ϭ 279) and meropenem-nonsusceptible (n ϭ 296) isolates. Ceftazidime-avibactam activity against ceftazidime-nonsusceptible P. aeruginosa (76.7% susceptible to ceftazidime-avibactam) was significantly greater than those for cefepime, meropenem, and piperacillin-tazobactam (31.9%, 40.1%, and 15.4% susceptible, respectively); moreover, ceftazidime-avibactam retained this improved in vitro potency against meropenem-nonsusceptible P. aeruginosa (81.1% ceftazidime-avibactam susceptible) isolates (40.5% to 46.3% susceptible to ceftazidime, cefepime, and piperacillin-tazobactam). It is interesting that, of the 144 P. aeruginosa isolates (8.3%) that were not susceptible to ceftazidime, meropenem, and piperacillin-tazobactam, 94 (65.3%) were susceptible to ceftazidime-avibactam (Fig.  2) at the FDA-approved breakpoint (12) . In other studies, ceftazidime-avibactam resistance in P. aeruginosa isolates was primarily the result of decreased membrane permeability and upregulated efflux mechanisms and less frequently the result of a loss of outer membrane porins or the production of class B or D ␤-lactamases (13, 14) .
The high level of in vitro activity observed for ceftazidimeavibactam against P. aeruginosa was corroborated by an additional study that showed similar activity (67.4% susceptible to ceftazidime-avibactam) against 396 P. aeruginosa isolates, obtained between 2011 and 2014, with nonsusceptibility to ceftazidime, cefepime, meropenem, and piperacillin-tazobactam (15) .
In each of the census regions, ceftazidime-avibactam consistently demonstrated higher susceptibility rates than comparators commonly used as first-line agents for the treatment of P. aeruginosa infections. The potent in vitro activity observed in this surveillance study for ceftazidime-avibactam against P. aeruginosa isolates, including significant activity against isolates that are not susceptible to ceftazidime, meropenem, and piperacillin-tazobactam, highlight the potential clinical utility of this antibacterial combination against serious difficult-to-treat P. aeruginosa infection. These in vitro surveillance results also reinforce and support existing clinical data regarding ceftazidime-avibactam activity against P. aeruginosa.
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